-
CTCX Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Carmell Therapeutics (CTCX)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.14 mm | 1.14 mm | 1.14 mm | 1.14 mm | 1.14 mm | 1.14 mm |
Cash burn (monthly) | 353.65 k | 496.55 k | 959.49 k | 839.10 k | 467.54 k | 585.67 k |
Cash used (since last report) | 1.29 mm | 1.82 mm | 3.51 mm | 3.07 mm | 1.71 mm | 2.14 mm |
Cash remaining | -157.12 k | -680.16 k | -2.37 mm | -1.93 mm | -574.00 k | -1.01 mm |
Runway (months of cash) | -0.4 | -1.4 | -2.5 | -2.3 | -1.2 | -1.7 |
13F holders | Current |
---|---|
Total holders | 17 |
Opened positions | 10 |
Closed positions | 1 |
Increased positions | 2 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 343.03 mm |
Total shares | 3.82 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Newlin Investment Co 1 | 1.25 mm | $0.00 |
SANDSTONE Asset Management | 1.02 mm | $2.65 mm |
Linden Capital | 371.25 k | $0.00 |
Integrated Core Strategies | 235.41 k | $829.00 k |
Hubbell Strickland Wealth Management | 205.52 k | $82.52 mm |
Vanguard | 182.00 k | $73.16 mm |
Carnegie Mellon University | 134.47 k | $53.99 mm |
Geode Capital Management | 98.17 k | $39.42 mm |
Exos Asset Management | 78.10 k | $4.69 mm |
BlackRock | 63.15 k | $25.36 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Oct 24 | Gilles Spenlehauer | Stock Option Common Stock | Grant | Acquire A | No | No | 0.358 | 76,878 | 27.52 k | 76,878 |
11 Oct 24 | Richard A Upton | Stock Option Common Stock | Grant | Acquire A | No | No | 0.358 | 76,878 | 27.52 k | 76,878 |
11 Oct 24 | Kathryn Gregory | Stock Option Common Stock | Grant | Acquire A | No | No | 0.358 | 76,878 | 27.52 k | 76,878 |
11 Oct 24 | Scott M. Frisch | Stock Option Common Stock | Grant | Acquire A | No | No | 0.358 | 76,878 | 27.52 k | 76,878 |
11 Oct 24 | Rajiv Shukla | Stock Option Common Stock | Grant | Acquire A | No | No | 0.358 | 876,878 | 313.92 k | 876,878 |